Glancy Prongay Wolke & Rotter LLP is continuing an investigation into possible federal securities-law violations by Alignment Healthcare, Inc. on behalf of investors. The inquiry follows a former executive’s whistleblower lawsuit alleging that Alignment classified routine technology operating costs, including software maintenance and production support, as capital expenditures. The alleged accounting treatment artificially increased adjusted EBITDA and helped the company report its first full year of positive adjusted EBITDA as a public company, while also affecting metrics tied to its stock price and executive compensation. Alignment shares fell $4.02, or 16.7%, to close at $20.03 on July 8, 2026, after reports of the lawsuit emerged. The investigation follows separate investor inquiries by Hagens Berman and The Law Offices of Frank R. Cruz. Investors with losses and people with non-public information have been invited to contact the investigating firms, including about possible participation in the SEC Whistleblower Program, which can provide rewards of up to 30% of a successful recovery.